Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

2012333 citationsJournal Articlehybrid Open Access

Authors

Bernard Zinman · University of Toronto

Athena Philis‐Tsimikas · Scripps Whittier Diabetes Institute

Bertrand Cariou · Institut du Thorax

Yehuda Handelsman · Tarzana Treatment Centers

Helena W. Rodbard

Thue Johansen · Novo Nordisk (Denmark)

Lars Endahl · Novo Nordisk (Denmark)

Abstract

Insulins degludec and glargine administered once daily in combination with OADs provided similar long-term glycemic control in insulin-naive patients with type 2 diabetes, with lower rates of nocturnal hypoglycemia with degludec.

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 35, Issue 12, pp. 2464-2471

DOI: 10.2337/dc12-1205

Field-Weighted Citation Impact: 23.01